Clinical trials: Respiratory Syncytial Viruses
Atopic Asthma, Recurrent Wheezing
Effects of Preventive Treatment for Respiratory Syncytial (RS) Virus Infection During Infancy on Later Atopic Asthma in Preterm Infants
The primary objective of the study is to determine whether the incidence of atopic asthma after three years old may be suppressed in the children who were born as preterm infants and prophylactically treated with palivizumab for…
- Trial name
- NCT01545245
- Volunteers
- 343 people
- Sponsor
- Tokai University
Healthy
A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants
Primary objective of this study is to describe the safety and tolerability of multiple doses of MEDI-534 in children 6 to less than (<) 24 months of age and in infants 2 months of age.
- Trial name
- NCT00686075
- Testing
- MEDI-534, Cohort 1, MEDI-534, Cohort 2, MEDI-534, Cohort 3
- Where
- 100 sites in United States, Australia and 7 more
- Volunteers
- 1,338 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Respiratory Syncytial Virus (RSV) Infection, Respiratory Syncytial Virus Hospitalizations
The Impact of the 2025 Infant and Maternal Respiratory Syncytial Virus (RSV) Prevention Program on RSV-related Hospitalisations in the Australian Capital Territory
The goal of this observational study is to is to examine the impact of new RSV prevention medicines on the burden of RSV disease among young children.
- Conditions
- Respiratory Syncytial Virus (RSV) Infection, Respiratory Syncytial Virus Hospitalizations, Respiratory Syncytial Virus Immunization
- Trial name
- NCT07164430
- Where
- Australia
- Volunteers
- 2,792 people
- Sponsor
- Nicola Irwin
Healthy Adult Participants
Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated With RSV
Double-Blind, Randomised, Placebo-Controlled Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated with Respiratory Syncytial Virus (RSV).
- Trial name
- NCT04540627
- Testing
- Palivizumab, RSV-A Memphis 37b virus
- Where
- United Kingdom
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- mAbxience Research S.L.
Respiratory Syncytial Virus Infection
Safety and Immunogenicity of the Recombinant Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 18 Years and Older
This phase 1 study in China will evaluate the safety and immunogenicity of the the Respiratory Syncytial Virus (RSV) Vaccine, LYB005 in adults aged 18 years and older.
- Trial name
- NCT06904222
- Testing
- Low dose antigen of LYB005 without A01B adjuvant, Low dose antigen of LYB005 with A01B adjuvant, Middle dose antigen of LYB005 without A01B adjuvant
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
Pneumococcal Infections, Respiratory Syncytial Virus (RSV) Infection
In-depth Analysis of the Immune Responses in the Upper Respiratory Tract in Older Adults Infected or Colonized With Streptococcus Pneumoniae (Spn)
The NoseSpn-Elderly study aims at characterizing the immune response in the upper respiratory tract in adults aged 60 and over diagnosed with a pneumonia due to a Streptococcus pneumoniae (Spn) infection.
- Conditions
- Pneumococcal Infections, Respiratory Syncytial Virus (RSV) Infection, Influenza Infection
- Trial name
- NoseSpnElderly (NCT06998251)
- Where
- Switzerland
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- University Hospital, Geneva
Lower Respiratory Tract Infection
Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in China
The purpose of this study is to evaluate the Safety and Efficacy of Nirsevimab, in Healthy Preterm and Term Infants in China
- Trial name
- CHIMES (NCT05110261)
- Testing
- Nirsevimab
- Where
- 30 sites in China
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Immunocompromised Patients
Immunogenicity and Safety of Two Respiratory Syncytial Virus Vaccine Strategies in Lung and Allogeneic Haematopoietic Stem Cell Transplant Recipients.
Respiratory syncytial virus (RSV) is a major cause of acute respiratory infections (ARIs), which occur in seasonal outbreaks. Among the adult population, immunocompromised individuals, particularly lung transplant recipients and…
- Trial name
- RSVAxID (NCT07863401)
- Testing
- RSVpreF3-AS01, RSVpreF3
- Where
- 16 sites in France
- Volunteers
- 400 people
- Sponsor
- Hospices Civils de Lyon
Respiratory Syncytial Virus
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age
The main purposes of Part A of this study are to evaluate the safety, tolerability, and immunogenicity of mRNA-1345 coadministered with a seasonal influenza vaccine (Afluria® Quadrivalent); to evaluate the impact of…
- Trial name
- RSVictory (NCT05330975)
- Testing
- mRNA-1345, Afluria® Quadrivalent, mRNA-1273.214
- Where
- 62 sites in United States
- Volunteers
- 3,317 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Respiratory Syncytial Virus Prevention
A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention of Respiratory Syncytial Virus (RSV) Mediated- Lower Respiratory Tract Disease (LRTD) in Japanese Participants
The purpose of the study is to evaluate the efficacy of study vaccine in the prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-confirmed RSV mediated- lower Respiratory Tract Disease (LRTD) over one RSV…
- Trial name
- NCT05242432
- Testing
- Ad26/protein preF RSV Vaccine
- Where
- 30 sites in Japan
- Volunteers
- 2,192 people
- Sponsor
- Janssen Pharmaceutical K.K.
RSV
Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to ≤49 Years of Age
This randomized, double-blinded, placebo-controlled Phase 3 study is designed to evaluate the safety, tolerability, and immunogenicity of 3 lots of RSVpreF in healthy adults.
- Trial name
- NCT05096208
- Testing
- RSVpreF (Group 1), RSVpreF (Group 2), RSVpreF (Group 3)
- Where
- 18 sites in United States
- Volunteers
- 1,028 people, healthy volunteers welcome
- Sponsor
- Pfizer